CL2021001096A1 - Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196) - Google Patents

Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196)

Info

Publication number
CL2021001096A1
CL2021001096A1 CL2021001096A CL2021001096A CL2021001096A1 CL 2021001096 A1 CL2021001096 A1 CL 2021001096A1 CL 2021001096 A CL2021001096 A CL 2021001096A CL 2021001096 A CL2021001096 A CL 2021001096A CL 2021001096 A1 CL2021001096 A1 CL 2021001096A1
Authority
CL
Chile
Prior art keywords
myelodysplastic syndrome
methods
mds
subject
divisional application
Prior art date
Application number
CL2021001096A
Other languages
English (en)
Inventor
Aleksandra Rizo
Jacqueline Cirillo Bussolari
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63209674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2021001096(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Geron Corp filed Critical Geron Corp
Publication of CL2021001096A1 publication Critical patent/CL2021001096A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La divulgación proporciona métodos para tratar un síndrome mielodisplásico (MDS) en un sujeto que no ha recibido tratamiento con un agente seleccionado de un agente de hipometilación (HMA) y lenalidomida, o ambos. El método incluye administrar al sujeto una cantidad eficaz de un inhibidor de la telomerasa, como por ejemplo, el imetelstat o el sodio de imetelstat. En algunos casos, el sujeto tratado se clasifica como con MDS de riesgo bajo/intermedio-1 de IPSS y/o que tiene MDS recidivante/resistente a agente estimulante de la eritropoyesis (ESA).
CL2021001096A 2017-07-28 2021-04-28 Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196) CL2021001096A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762538315P 2017-07-28 2017-07-28
US201762595329P 2017-12-06 2017-12-06
US201862685542P 2018-06-15 2018-06-15

Publications (1)

Publication Number Publication Date
CL2021001096A1 true CL2021001096A1 (es) 2021-11-12

Family

ID=63209674

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2020000196A CL2020000196A1 (es) 2017-07-28 2020-01-23 Métodos para tratar el síndrome mielodisplásico.
CL2021001096A CL2021001096A1 (es) 2017-07-28 2021-04-28 Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2020000196A CL2020000196A1 (es) 2017-07-28 2020-01-23 Métodos para tratar el síndrome mielodisplásico.

Country Status (18)

Country Link
US (1) US12171778B2 (es)
EP (1) EP3658156B1 (es)
JP (4) JP7316261B2 (es)
KR (2) KR102867725B1 (es)
CN (2) CN121243203A (es)
AU (2) AU2018307983B2 (es)
BR (1) BR112020001749A2 (es)
CA (1) CA3069010A1 (es)
CL (2) CL2020000196A1 (es)
IL (2) IL324714A (es)
MA (1) MA49688A (es)
MX (1) MX2025005894A (es)
NZ (2) NZ802272A (es)
SG (1) SG11201913984RA (es)
TW (2) TWI879717B (es)
UA (1) UA127701C2 (es)
WO (1) WO2019023667A1 (es)
ZA (1) ZA202000070B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
KR102867725B1 (ko) 2017-07-28 2025-10-13 제론 코포레이션 골수형성이상 증후군의 치료 방법
UA130012C2 (uk) 2018-11-29 2025-10-15 Джерон Корпорейшн Спосіб лікування мієлодиспластичного синдрому
JP2023534295A (ja) 2020-07-17 2023-08-08 ジェロン・コーポレーション 皮下テロメラーゼ阻害剤組成物及びそれらを使用するための方法
CN116887844A (zh) * 2021-01-18 2023-10-13 活跃生物技术有限公司 用于治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
IL107150A0 (en) 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
CN1317291C (zh) 1999-09-10 2007-05-23 杰龙公司 寡核苷酸n3′→p5′硫代氨基磷酸酯,其合成及应用
US7321029B2 (en) 2000-01-21 2008-01-22 Geron Corporation 2′-arabino-fluorooligonucleotide N3′→P5′ phosphoramidates: their synthesis and use
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
AU2002245717A1 (en) 2001-03-23 2002-10-08 Geron Corporation Oligonucleotide conjugates
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
CN100393209C (zh) 2003-09-09 2008-06-11 杰龙公司 用于端粒酶抑制的改性寡核苷酸
ATE503014T1 (de) 2003-11-04 2011-04-15 Geron Corp Rna-amidate und thioamidateur rnai
US20050282893A1 (en) 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
ME02933B (me) 2004-07-02 2018-04-20 Geron Corp Sinteza zaštićenih 3'-amino nukleozionih monomera
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
WO2006113426A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
EP1876893B1 (en) 2005-04-15 2012-04-11 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
CA2615574A1 (en) 2005-07-29 2007-02-08 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
WO2007127163A2 (en) 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
SI2898887T1 (sl) 2006-10-30 2019-01-31 Geron Corporation Kombinirani telomerazni inhibitor in gemcitabin za zdravljenje raka
WO2008094640A2 (en) 2007-01-30 2008-08-07 Geron Corporation Compounds having anti-adhesive effects on cancer cells
US9155753B2 (en) 2007-03-09 2015-10-13 Geron Corporation Treatment of carcinomas with a combination of EGF-pathway and telomerase inhibitors
US8367078B2 (en) 2007-06-06 2013-02-05 University Of Florida Research Foundation, Inc. Kinase inhibitor compounds
CN101220044B (zh) 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途
US8044240B2 (en) 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
EP2304436A1 (en) 2008-07-10 2011-04-06 Nodality, Inc. Methods for diagnosis, prognosis and treatment
LT3029154T (lt) 2008-10-17 2017-12-27 Geron Corporation Paciento jautrumo telomerazės slopinimo terapijai nustatymo būdas
WO2011017096A2 (en) 2009-08-04 2011-02-10 Mayo Foundation For Medical Education And Research Methods of treating hematologic cancers
ES2616055T3 (es) 2010-02-12 2017-06-09 Qiagen Marseille ASXL1 como nuevo marcador de diagnóstico de neoplasias mieloides
WO2012149339A2 (en) 2011-04-29 2012-11-01 Sequenom, Inc. Quantification of a minority nucleic acid species
WO2013056211A2 (en) 2011-10-13 2013-04-18 H. Lee Moffitt Cancer Center & Research Institute, Inc. Telomerase reverse transcriptase deficience as diagnostic marker of myelodysplastic syndrome
WO2013059738A2 (en) 2011-10-19 2013-04-25 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
ES2874774T3 (es) 2011-12-22 2021-11-05 Geron Corp Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
CA2892445C (en) 2012-11-30 2022-06-28 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
UA128370C2 (uk) 2012-12-07 2024-06-26 Джерон Корпорейшн Використання інгібітора теломерази для лікування мієлопроліферативних неоплазм
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US20150342982A1 (en) * 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
US20160022708A1 (en) 2013-03-14 2016-01-28 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
PL3065828T3 (pl) * 2013-11-06 2019-06-28 Mayo Foundation For Medical Education And Research Sposoby i materiały do leczenia złośliwych nowotworów hematologicznych
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
KR102867725B1 (ko) 2017-07-28 2025-10-13 제론 코포레이션 골수형성이상 증후군의 치료 방법

Also Published As

Publication number Publication date
AU2024219941A1 (en) 2024-10-10
ZA202000070B (en) 2025-09-25
JP7316261B2 (ja) 2023-07-27
WO2019023667A1 (en) 2019-01-31
NZ802277A (en) 2026-03-27
MX2025005894A (es) 2025-06-02
UA127701C2 (uk) 2023-12-06
EP3658156A1 (en) 2020-06-03
KR102867725B1 (ko) 2025-10-13
SG11201913984RA (en) 2020-02-27
JP7654761B2 (ja) 2025-04-01
JP2025013669A (ja) 2025-01-24
TW202432146A (zh) 2024-08-16
US20190030064A1 (en) 2019-01-31
MA49688A (fr) 2020-06-03
AU2018307983A1 (en) 2020-02-13
US12171778B2 (en) 2024-12-24
TWI906757B (zh) 2025-12-01
NZ760873A (en) 2024-03-22
IL324714A (en) 2026-01-01
CN121243203A (zh) 2026-01-02
IL272163A (en) 2020-03-31
AU2018307983B2 (en) 2024-07-18
KR20200033269A (ko) 2020-03-27
IL272163B1 (en) 2025-12-01
CN110944646A (zh) 2020-03-31
TWI879717B (zh) 2025-04-11
TW201919705A (zh) 2019-06-01
CL2020000196A1 (es) 2020-11-20
JP2024015000A (ja) 2024-02-01
JP7654615B2 (ja) 2025-04-01
JP2023009229A (ja) 2023-01-19
JP2020528915A (ja) 2020-10-01
NZ802272A (en) 2026-03-27
CA3069010A1 (en) 2019-01-31
KR20250151565A (ko) 2025-10-21
BR112020001749A2 (pt) 2020-07-21
EP3658156B1 (en) 2026-03-25

Similar Documents

Publication Publication Date Title
CL2021001096A1 (es) Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196)
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
ECSP20082339A (es) Moduladores de la expresión de apol1
MX2024012816A (es) Metodos para tratar y/o prevenir la enfermedad de injerto contra huesped y/o la hemorragia alveolar difusa y/o la enfermedad venooclusiva asociada al trasplante de celulas madre hematopoyeticas
MX382902B (es) Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
CR20210103A (es) Composición farmacéutica para usarse en el tratamiento o prevención de una enfermedad relacionada con c5 y método para tratar o prevenir una enfermedad relacionada con c5
BR112017006406A2 (pt) composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
MX2019014667A (es) Tratamiento de trastornos cutaneos.
PE20210109A1 (es) Moduladores de la expresion de irf4
MX2018001608A (es) Composicion densificada para el tratamiento de una formacion subterranea.
UY38720A (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
CO2021007006A2 (es) Moduladores de la expresión de irf5
CL2021000107A1 (es) Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma
CL2021001386A1 (es) Métodos de tratamiento del síndrome mielodisplásico
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
UY38472A (es) Moduladores de la expresión de foxp3
MX2020003554A (es) Moduladores de la expresion de enac.
BR112021006388A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero
AR112288A1 (es) Métodos para tratar el síndrome mielodisplásico
BR112017016596A2 (pt) composição farmacêutica para prevenir ou tratar a leucemia mieloide crônica, e método de prevenção ou tratamento da leucemia mieloide crônica de um sujeito
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol